Today: 8 February 2026
Subscribe

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Company Background and Business Model Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in RNA interference (RNAi) therapies for cancer. The company was co-founded by Nobel laureate Dr. Craig Mello, a discoverer of RNAi, leveraging that legacy to develop its proprietary INTASYL™ gene-silencing technologyphiopharma.com. Originally known as RXi Pharmaceuticals (founded ~2011), Phio rebranded and refocused on immuno-oncology. Its mission is to use small interfering RNA (siRNA) to “silence” genes that allow tumors to evade the immune system, thereby empowering the body’s own defenses to fight cancerragingbull.com. Headquartered in Pennsylvania (King of Prussia) with R&D roots in Massachusetts, Phio is
3 November 2025
··
ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

Recent News and Updates (Early November 2025) Earnings Release: On November 3, 2025, ON Semiconductor announced its third-quarter 2025 financial results, which were better than expected. The company reported Q3 revenue of $1.55 billion (down roughly 11% year-over-year) and a profit of $255 million Timesunion Timesunion. Earnings came out to $0.63 per diluted share, beating Wall Street’s consensus of $0.60. This marks a positive surprise given the headwinds the company faced earlier in the year. Management noted that the results “exceeded expectations, underscoring the strength of our strategy and the resilience of our business model,” according to CEO Hassane El-Khoury Tradingview. He
3 November 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

Stock Performance: Skyrockets and Crashes UniQure’s stock has been on a wild ride in 2025. After starting the year in the mid-teens, QURE shares skyrocketed through mid-2025 on hopes for its Huntington’s gene therapy. The rally hit a fever pitch in late September when Phase 1/2 trial data showed a remarkable 75% reduction in disease progression with AMT-130 – news that caused the stock to surge almost 200% that monthreuters.com. By late October, QURE was hovering around $68–$70, up roughly 300–500% from spring levels. However, in the past few days the stock’s momentum sharply reversed. On Monday, Nov 3, 2025,
3 November 2025
·
MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

Leadership Transition at MongoDB MongoDB’s announcement on November 3, 2025 signaled a major leadership shake-up for the $29 billion database company. Dev Ittycheria, who has served as CEO since 2014, will be stepping down after an 11-year tenure leading MongoDBmarkets.ft.com. Ittycheria is credited with transforming MongoDB from a startup into a global player – he oversaw the company’s 2017 IPO and the growth of its customer base to nearly 60,000 organizations (including over 75% of the Fortune 100)markets.ft.cominvesting.com. In the press release, Ittycheria called it “the privilege of a lifetime to lead MongoDB” and said he is “immensely grateful to our
3 November 2025
··
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Stock Price and Recent Performance Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peak (~$50)sharewise.com. In the past three years, the shares have tumbled about 50% as the company’s COVID-fueled revenue boom faded and investors braced for patent expirationssharewise.com. By mid-2025, Pfizer traded near multi-year lows (around $23), though it bounced off those lows in early October after positive news on earnings and policy. Notably, Pfizer’s stock surged ~15% at the end of Q3 (from ~$23.85 on Sept. 29 to ~$27.37 by Oct. 3statmuse.comstatmuse.com)
3 November 2025
·
Amazon Stock Skyrockets to Record High on AWS Boom – Analysts Predict More Upside

Amazon Stock Skyrockets to Record High on AWS Boom – Analysts Predict More Upside

Amazon Stock Price: Record High After Earnings Surge Amazon’s stock is riding high after its latest earnings triumph. Shares of AMZN skyrocketed ~10% on Friday, Oct. 31 following the Q3 report, pushing the stock to an all-time high in the mid-$240s per sharereuters.com. That one-day pop – Amazon’s biggest in years – added roughly $200 billion to its market capitalization and lifted the stock’s year-to-date performance into double-digit gains. Prior to the earnings, Amazon had been a notable laggard among Big Tech peers in 2025 (up only ~1.6% YTD), but the post-earnings rally has “helped pull Amazon out of that
3 November 2025
··
Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

The 1300% Rally and Meme Stock Frenzy Opendoor’s stock has experienced a jaw-dropping rally in 2025, transforming from a penny-stock into a retail trading sensation. After languishing below $1 per share through mid-year (and drawing a Nasdaq delisting warning), OPEN caught fire over the summer. A coalition of individual investors on Reddit and X (formerly Twitter) began touting Opendoor as the next big “meme stock,” similar to past hits like GameStop and AMCnasdaq.com. This social-media enthusiasm, combined with activist investor pressure, ignited a massive short squeeze and sent Opendoor shares rocketing up around 1,300% from their lowsnasdaq.com. The stock exploded
3 November 2025
·
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Company Overview and Background Acrivon Therapeutics is a Boston-area biotech (NASDAQ: ACRV) founded in 2018, emerging with a mission to revolutionize cancer treatment through precision medicinestockanalysis.com. The company’s name “Acrivon” is derived from “accurate” or “precision,” reflecting its core approach: develop targeted oncology drugs hand-in-hand with diagnostics that pinpoint the patients who will respond. Acrivon’s proprietary platform, AP3 (Acrivon Predictive Precision Proteomics), lies at the heart of this strategy. Using proteomics and AI tools, AP3 measures the activity of myriad proteins and signaling pathways inside tumor cells in their native state, rather than just analyzing DNA mutationsglobenewswire.comglobenewswire.com. This allows Acrivon
3 November 2025
·
NIO Stock Skyrockets on Record Sales and Bold Moves – Can the Rally Last?

NIO Stock Skyrockets on Record Sales and Bold Moves – Can the Rally Last?

NIO Stock Performance: Latest Price and Short-Term Trend NIO’s stock has been on a notable upswing heading into November 2025. Shares closed at $7.25 on October 31, 2025 – a multi-month high – after jumping over 3% in a single day following the latest delivery reportstockinvest.us. This capped a strong week; NIO gained roughly 5.1% over the last week of October, even though it was still down a few percent over the full monthsimplywall.st. The late-October bounce reflects renewed investor enthusiasm around the company’s record sales figures and growth trajectory. It’s worth noting that NIO’s current price around $7+ represents
3 November 2025
·
TGE Stock’s Wild Ride: Why The Generation Essentials Group Is Making Headlines in Nov 2025

TGE Stock’s Wild Ride: Why The Generation Essentials Group Is Making Headlines in Nov 2025

Recent Stock Performance and Volatility (Late Oct – Early Nov 2025) TGE’s stock has experienced a rollercoaster in recent days, capturing investors’ attention. In the final week of October 2025, shares entered a freefall: between October 27 and October 31 the price plunged from highs near $1.89 to a low of $0.7777 intraday on Oct 31 Stockstotrade. The October 31 session was especially dramatic – TGE opened around $1.79 but collapsed over 50%, hitting that record low of $0.78 before closing at $1.01 Stockstotrade Stockstotrade. This marked a single-day drop of ~54%, capping a multi-day slide in which the stock
3 November 2025
·
IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀

IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀

Company Overview & Business Segments IDEXX Laboratories facility in Markham, Canada (one of the company’s global offices). IDEXX Laboratories, Inc. is a veterinary diagnostics and life sciences company that develops, manufactures, and sells products and services for animal health and water testing in over 175 countries Pestel Analysis Pestel Analysis. Founded in 1983 and headquartered in Maine, IDEXX has grown into the dominant player in pet healthcare diagnostics, as well as a significant provider in livestock/poultry and water microbiology testing. The company operates through three main business segments Wikipedia: Across these segments, IDEXX’s business model is built on selling durable
3 November 2025
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

RANI Stock Performance: From Penny Stock to Momentum Rocket Rani Therapeutics’ stock price has been on a tear in late 2025, turning heads in the biotech investing community. After languishing under $1 for most of the year, RANI exploded upward in October. It closed on Oct 31 at $2.20, up +51.7% in one dayfinviz.com on massive volume (~61 million shares vs ~15 million averagefinviz.com). In fact, over the past month RANI has climbed about 335%finviz.com. Just a few weeks ago in early October it was trading around 50–60 cents; by the first week of November it’s oscillating in the mid-$2s.
3 November 2025
·
MSP Recovery (MSPR) Stock Skyrockets 100% Amid Delisting Drama – What’s Next for This Troubled Company?

MSP Recovery (MSPR) Stock Skyrockets 100% Amid Delisting Drama – What’s Next for This Troubled Company?

In short: MSP Recovery’s stock is trading at mere pennies after a spectacular rise-and-fall on Nov 3. The company is fighting for survival – juggling emergency financings, a looming Nasdaq delisting, and ongoing legal battles – all while attempting to transform its fortunes in the healthcare reimbursement industry. Company Overview: Business Model & Financials Business Model: MSP Recovery, Inc. is a 2014-founded Miami-based company that aims to recover reimbursements from Medicare, Medicaid, and other insurers on behalf of healthcare payerstipranks.com. Under the Medicare Secondary Payer (MSP) Act, if a private insurer should have paid a claim that Medicare/Medicaid covered, that
3 November 2025
·
Dell Stock Skyrockets on AI Boom – Price Surge, Key News & 2025 Outlook

Dell Stock Skyrockets on AI Boom – Price Surge, Key News & 2025 Outlook

Dell Technologies (NASDAQ: DELL) stock is trading around $162 per share as of Nov. 3, 2025, near its 52-week high after a massive rally fueled by booming demand for AI serversmarketbeat.com. Shares have more than doubled in the past year (12-month low ~$66, high ~$168) and are up roughly 35% year-to-date, far outperforming the S&P 500 and most tech peersmarketbeat.com. In the last few days, major news – including a $5.8 billion AI hardware deal tied to Microsoft – has driven the stock higherreuters.com. Analysts remain bullish, citing Dell’s raised growth forecasts and strong positioning in enterprise AI, while company executives
3 November 2025
·
ALPS Group (NASDAQ: ALPS) Stock’s Wild Debut – Biotech Unicorn’s SPAC Merger Sparks Volatile Trading

ALPS Group (NASDAQ: ALPS) Stock’s Wild Debut – Biotech Unicorn’s SPAC Merger Sparks Volatile Trading

Sources: Financial data from Yahoo Finance/Refinitivreuters.comreuters.com and company filings; GlobeNewswire press releaseglobenewswire.comglobenewswire.com; Reuters news reportreuters.com; Bernama (Malaysia) interview with CEObernama.combernama.com; Stock analysis sites and SEC filings for market cap and float detailsfinviz.comstocktitan.net. All statements and quotes are cited from these sources.
3 November 2025
·
Berkshire Hathaway’s Next Act: Trillion-Dollar BRK-B, Buffett’s Farewell & 2025 Forecasts

Berkshire Hathaway’s Next Act: Trillion-Dollar BRK-B, Buffett’s Farewell & 2025 Forecasts

Current Price & Recent Performance Berkshire Hathaway’s Class B stock (NYSE: BRK-B) trades around $477–$480 as of early November 2025stockinvest.us. The share price has eased off about 5% since mid-October, when it briefly crossed the $500 mark before pulling backstockinvest.us. Year-to-date, BRK-B is up roughly 8–9% in 2025, which means it has underperformed the S&P 500 (the S&P is up about 14–16% over the same period)tipranks.com. Berkshire’s stock had been at record highs earlier in the year, but it fell back after CEO Warren Buffett announced his retirement plans in May – since that news, the stock has lagged the broader
3 November 2025
··
Datavault AI (DVLT) Stock Skyrockets on AI Frenzy – Key Facts & Future Outlook

Datavault AI (DVLT) Stock Skyrockets on AI Frenzy – Key Facts & Future Outlook

Company Overview and Business Model Datavault AI Inc. is a young technology company at the intersection of artificial intelligence, blockchain, and data monetization. Its mission is to help organizations turn underutilized data into valuable assets. To do this, Datavault provides a cloud-based platform that combines high-performance computing (HPC) and Web 3.0 data management. In practice, the company’s software enables clients to securely manage their data (often on a blockchain ledger), “tokenize” data into digital assets, and create digital twins (virtual representations) of real-world datastocktitan.netstocktitan.net. This allows the data to be bought, sold, or licensed on exchanges, potentially unlocking new revenue
3 November 2025
···
AMTD Digital (HKD) Skyrockets 180% on 1,085% Revenue Surge – Meme-Stock Mania 2.0 or Sustainable Comeback?

AMTD Digital (HKD) Skyrockets 180% on 1,085% Revenue Surge – Meme-Stock Mania 2.0 or Sustainable Comeback?

Company Overview & Background AMTD Digital Inc. is a subsidiary of the AMTD Group conglomerate and part of a broader family that includes parent AMTD IDEA Group (NYSE: AMTD). Founded in 2019 and initially based in Hong Kong, AMTD Digital positioned itself as a “one-stop” digital solutions platform. Its original business lines span digital financial services, the AMTD SpiderNet ecosystem (a connector network for Asian entrepreneurs), digital media, content & marketing, and digital investments in tech startupsreuters.comchartmill.com. The company capitalized on AMTD Group’s fintech roots – leveraging various financial licenses in Asia – while also investing in content and digital
3 November 2025
Micron’s AI-Fueled Stock Surge: Record Earnings, Rallying Shares & What’s Next for MU

Micron’s AI-Fueled Stock Surge: Record Earnings, Rallying Shares & What’s Next for MU

Business Overview and Market Position Micron Technology, Inc. is a leading semiconductor manufacturer specializing in memory and data storage chips. Its product portfolio includes dynamic random access memory (DRAM) chips – used in PCs, servers, and smartphones – and NAND flash memory for data storage in devices like solid-state drives. Micron is also at the forefront of new memory technologies such as High-Bandwidth Memory (HBM), a specialized high-speed DRAM used in advanced AI accelerators and graphics processorsreuters.com. These memory products are critical components in modern computing infrastructure, from cloud data centers to personal gadgets. With a market capitalization around $250 billionmarketbeat.com,
3 November 2025
···
FuboTV’s Big Score: Disney Hulu Deal and Surprise Profit Spark Stock Surge

FuboTV’s Big Score: Disney Hulu Deal and Surprise Profit Spark Stock Surge

FuboTV Stock Rallies on Earnings and Disney Deal FuboTV’s stock is on the move after a one-two punch of strong earnings and a transformational Disney partnership. As of November 3, 2025, FUBO shares traded around $3.90, up roughly 5% from the prior closeinvesting.com. The latest Q3 earnings surprise – featuring better-than-expected revenue and a swing to adjusted profit – sent investors piling in, reflecting newfound optimism about Fubo’s direction. This continues a dramatic run for FUBO stock in 2025, which has climbed nearly 200% year-to-date as anticipation built for Fubo’s merger with Disney’s Hulu Live TV unitfinanchill.comfinanchill.com. Fubo’s market capitalization
3 November 2025
1 … 1,380 1,381 1,382 1,383 1,384 … 1,641

Stock Market Today

CapitaLand Investment share price jumps into earnings week as 9CI closes at S$3.12

CapitaLand Investment share price jumps into earnings week as 9CI closes at S$3.12

8 February 2026
CapitaLand Investment shares closed up 1.3% at S$3.12 on Friday, outperforming the STI, which fell 0.83%. CapitaLand Integrated Commercial Trust reported a 16.4% rise in second-half distributable income to S$449 million and a 9.4% increase in distribution per unit. Full-year results for CapitaLand Investment are due Feb. 11. Markets are closed for the weekend.
Hongkong Land (SGX:H78) slides 4% despite fresh buyback as March results loom

Hongkong Land (SGX:H78) slides 4% despite fresh buyback as March results loom

8 February 2026
Hongkong Land shares fell 4.2% to $8.18 Friday, reversing earlier gains after hitting a decade high of $9.12 on Feb. 4. The company disclosed repurchases of 170,000 shares for cancellation at average prices above Friday’s close. Investors await March 5 annual results and details on an expanded $650 million buyback program. Trading volume stayed high.
Go toTop